Emerging research suggest this peptide, a dual agonist targeting both incretin and GIP , appears to offer a significant advancement for weight loss . Preliminary clinical tests have shown considerable losses in visceral tissue, conceivably surpassing other weight-loss therapies . Nevertheless , additional assessment is necessary to fully determine